Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older (MEDREV)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Hospitalization; Patient Admission; Aged

Treatments: Other: Collaborative Pharmaceutical Care

Study type: Interventional

Funder types: Other

Identifiers

NCT02598115

PREPS/2014/JMK-01

2015-A00421-48 (Other Identifier)

Details and patient eligibility

About

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older.

This is a cluster-randomized study with a stepped-wedge design. Clusters correspond to participating centers. A randomly selected center is crossed-over into the intervention every fifteen days after the start of inclusions.

Full description

The secondary objectives are to evaluate:

A. The potential and observed clinical impact of the implementation of collaborative pharmaceutical care.

B. The acceptance rate of pharmaceutical interventions during collaborative pharmaceutical care.

C. Avoidable costs related to the consumption of care generated by the occurrence of serious adverse drug reactions.

D. The satisfaction of health professionals concerning the transfer of information on the patient's drug therapy carried out as part of collaborative pharmaceutical care.

Enrollment: 622 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient or his/her legal representative was informed about the study
• The patient is admitted as an in-patient to one of the participating hospitals
• The patient is available for 3 months of follow-up

Exclusion criteria

• The subject is participating in another drug study
• The subject is under judicial protection
• It is impossible to correctly inform the patient or his/her legal representative
• The patient or his/her legal representative refuses to participate in the study
• The expected life span of the patient is less than the required 3 months of follow-up
• It is impossible to contact the patient after hospitalisation
• Hospitalizatin for longer than 21 days

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

622 participants in 2 patient groups

Before collarborative pharmaceutical care

No Intervention group

Description:

All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days. Days 1 to 15: all clusters in the "before arm" Days 16 to 30: 1 cluster in the "Collaborative Pharmaceutical Care" arm Days 31 to 45: 2 clusters in the "Collaborative Pharmaceutical Care" arm Days 46 to 60: 3 clusters in the "Collaborative Pharmaceutical Care" arm Days 61 to 75: 4 clusters in the "Collaborative Pharmaceutical Care" arm Days 76 to 90: 5 clusters in the "Collaborative Pharmaceutical Care" arm Days 91 to 105: all 6 clusters in the "Collaborative Pharmaceutical Care" arm

After collarborative pharmaceutical care

Experimental group

Description:

All clusters start in the "No Intervention" arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days. Days 1 to 15: all clusters in the "before arm" Days 16 to 30: 1 cluster in the "Collaborative Pharmaceutical Care" arm Days 31 to 45: 2 clusters in the "Collaborative Pharmaceutical Care" arm Days 46 to 60: 3 clusters in the "Collaborative Pharmaceutical Care" arm Days 61 to 75: 4 clusters in the "Collaborative Pharmaceutical Care" arm Days 76 to 90: 5 clusters in the "Collaborative Pharmaceutical Care" arm Days 91 to 105: all 6 clusters in the "Collaborative Pharmaceutical Care" arm

Treatment:

Other: Collaborative Pharmaceutical Care